>But if you think Stoll's lying, then that's another story.<
Most biotech CEO’s choose their words carefully in front of investors. They know that saying there are term sheets for a drug candidate is sufficiently vague to not be an actionable offense. Disclosing the mere existence of term sheets without disclosing the terms themselves is not a material item, IMO.
Market Data 
Markets 
AI
